Tom Waddell

机构：The Christie Hospital, The Christie NHS Foundation Trust · ORCID：0000-0001-5652-3829

发表论文 43 篇 · 总被引 1816 次 · h-index 13

代表论文

• Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial (2022 · The Lancet Oncology · 被引 296)
• Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study (2023 · European Urology · 被引 147)
• Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from 42-month follow-up of KEYNOTE-426. (2021 · Journal of Clinical Oncology · 被引 109)
• Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial (2023 · The Lancet Oncology · 被引 84)
• Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma: 5-year analysis of KEYNOTE-426. (2023 · Journal of Clinical Oncology · 被引 80)
• Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial (2025 · Nature Medicine · 被引 55)